Vaxcyte completes $1.15 billion equity and convertible‑note offerings to fund VAX‑31 program
Vaxcyte Inc. priced and closed concurrent public offerings of common stock, pre‑funded warrants and 1.50 % senior convertible notes due 2032, raising about $1.15 billion. The equity portion sold roughly 8.58 million shares at $64 each, while the note tranche totaled $575 million. Proceeds will support clinical development, manufacturing scale‑up and commercial preparation for its VAX‑31 pneumococcal vaccine, as well as other pipeline projects and general corporate purposes.
Why it matters
The capital raise provides Vaxcyte with runway to advance its late‑stage vaccine candidates, reducing financing risk for investors. The note terms include a 40 % conversion premium to the $64 share price, meaning conversion will only occur if the stock appreciates, limiting dilution unless the share price rises.
Key facts
- 1The company offered 8,584,375 shares of common stock at $64.00 per share. marketscreener.com
- 2Pre‑funded warrants to purchase 400,000 shares were sold at $63.999 per warrant. globenewswire.com
- 3The convertible senior notes have a 1.50 % annual interest rate and a principal amount of $575 million. marketscreener.com
- 4Underwriters have a 30‑day option to buy up to an additional 1,171,875 shares and up to $75 million of notes for over‑allotments. globenewswire.com
- 5The offerings are expected to close on October 9, 2026. globenewswire.com
- 6Net proceeds will be used for VAX‑31 adult and pediatric clinical programs, manufacturing capacity, commercial launch preparation, other pipeline R&D and general corporate purposes. globenewswire.com
Summary written by AlphAI AI Desk from 20 of 23 sources. Not investment advice. Figures are as stated by the linked sources.